Teladoc Health (NYSE:TDOC) Issues FY 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of -1.100–0.700 for the period, compared to the consensus EPS estimate of -0.870. The company issued revenue guidance of $2.5 billion-$2.6 billion, compared to the consensus revenue estimate of $2.5 billion. Teladoc Health also updated its Q1 2026 guidance to -0.450–0.350 EPS.

Teladoc Health Stock Performance

NYSE:TDOC traded up $0.12 during mid-day trading on Wednesday, hitting $4.66. The company’s stock had a trading volume of 6,087,236 shares, compared to its average volume of 6,532,484. Teladoc Health has a 1 year low of $4.40 and a 1 year high of $11.55. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.70 and a quick ratio of 2.60. The stock has a market cap of $826.12 million, a price-to-earnings ratio of -3.64 and a beta of 2.12. The business’s fifty day moving average is $6.11 and its two-hundred day moving average is $7.24.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.The business had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Analysts anticipate that Teladoc Health will post -1.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TDOC. Barclays started coverage on shares of Teladoc Health in a research note on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 price objective on the stock. Citigroup cut their price target on Teladoc Health from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Friday, January 9th. BMO Capital Markets assumed coverage on Teladoc Health in a research report on Thursday, November 13th. They set a “market perform” rating and a $8.00 price target on the stock. Zacks Research cut Teladoc Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Finally, Evercore decreased their target price on Teladoc Health from $9.00 to $8.00 and set an “in-line” rating on the stock in a research report on Thursday, October 30th. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Teladoc Health has an average rating of “Hold” and a consensus target price of $9.12.

Insider Transactions at Teladoc Health

In related news, insider Fernando M. Rodrigues sold 4,209 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $7.48, for a total transaction of $31,483.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Carlos Nueno sold 3,897 shares of the company’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $29,188.53. Following the sale, the insider directly owned 27,175 shares of the company’s stock, valued at $203,540.75. The trade was a 12.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 33,288 shares of company stock valued at $251,684. Insiders own 0.58% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vinva Investment Management Ltd purchased a new position in Teladoc Health in the fourth quarter worth approximately $245,000. Oxford Asset Management LLP acquired a new position in Teladoc Health during the fourth quarter worth $200,000. One68 Global Capital LLC purchased a new position in shares of Teladoc Health during the fourth quarter worth $182,000. Polymer Capital Management US LLC lifted its stake in Teladoc Health by 32.0% during the 4th quarter. Polymer Capital Management US LLC now owns 22,443 shares of the health services provider’s stock worth $157,000 after acquiring an additional 5,443 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in Teladoc Health in the 3rd quarter valued at about $145,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.